Lymph Node Excision — Cost, Top Hospitals & Success Rates | MyMedicPlus

Lymph node excision encompasses a spectrum of procedures — from minimally invasive diagnostic sampling to radical therapeutic lymphadenectomy — performed for both oncological staging and definitive surgical treatment. Lymph nodes are the primary surveillance stations of the adaptive immune system and are critical metastatic waypoints for most solid tumours. Their removal serves two distinct purposes: (1) diagnostic — obtaining tissue for histopathological, immunohistochemical, and molecular analysis; and (2) therapeutic — removing confirmed regional metastatic disease to achieve locoregional control and, in some cancers, improve survival.

The evolution of lymph node surgery over the past three decades has been shaped by landmark trials including ACOSOG Z0011 (breast cancer) and MSLT-1 (melanoma), which refined the indications for sentinel lymph node biopsy (SLNB) and demonstrated that complete lymphadenectomy is not always necessary for metastatic sentinel nodes. The modern approach seeks to obtain maximum diagnostic and therapeutic benefit while minimising morbidity — particularly lymphedema, the most debilitating long-term complication.

This guide covers the full spectrum: fine needle aspiration (FNA) and core needle biopsy for initial evaluation, excisional biopsy for definitive diagnosis (especially lymphoma), sentinel lymph node biopsy for staging, and complete regional lymph node dissection for therapeutic indications.

Lymph node biopsy or excision is indicated across a broad range of clinical scenarios:

Diagnostic Indications:

• Unexplained lymphadenopathy >1 cm lasting >4 weeks without a clear reactive cause — or any lymphadenopathy with constitutional symptoms (fever, night sweats, weight loss — 'B symptoms'), asymmetric distribution, hard/fixed texture, or supraclavicular/epitrochlear location (high suspicion for malignancy).
• Suspected lymphoma — excisional biopsy is the gold standard because lymphoma diagnosis requires intact nodal architecture for subtype classification (WHO Classification of Haematological Malignancies 2022).
• Suspected metastatic carcinoma — FNA or core biopsy can confirm malignancy and guide primary tumour workup when a discrete palpable node is accessible.
• Tuberculous lymphadenitis — the most common cause of lymphadenopathy in endemic regions; core biopsy with AFB culture and GeneXpert MTB/RIF is diagnostic.
• Sarcoidosis, cat-scratch disease, Kikuchi disease, Castleman disease — excisional biopsy often required for definitive diagnosis when FNA is inconclusive.

Oncological Staging — Sentinel Lymph Node Biopsy:

• Breast cancer: SLNB in clinically node-negative early breast cancer (cT1–T2 N0) for axillary staging. ACOSOG Z0011 trial established that women with 1–2 positive sentinel nodes who undergo breast-conserving surgery with whole-breast radiotherapy do not require completion axillary lymph node dissection (ALND).
• Cutaneous melanoma: SLNB for primary melanomas >0.8 mm Breslow thickness (T1b and above). The MSLT-1 trial demonstrated improved disease-free survival and provided accurate staging but did not show overall survival benefit from immediate complete lymphadenectomy in positive SN patients (MSLT-2 and DeCOG-SLT trials support observation in place of completion dissection when no palpable nodes).
• Vulvar cancer, penile cancer, Merkel cell carcinoma: SLNB recommended for staging clinically node-negative disease.
• SNOLL (Sentinel Node and Occult Lesion Localisation): Combined technique for non-palpable breast lesions using radioisotope injection around the tumour to simultaneously identify sentinel node and guide surgical excision.

Therapeutic Lymphadenectomy:

• Clinically or radiologically node-positive melanoma — therapeutic groin or axillary/cervical dissection.
• Confirmed axillary metastases in breast cancer beyond ACOSOG Z0011 criteria — >2 positive sentinel nodes, mastectomy planned, or post-neoadjuvant chemotherapy with residual nodal disease (ALLIANCE A011202 trial ongoing).
• Penile cancer and vulvar cancer — inguinal lymphadenectomy for confirmed nodal involvement.
• Thyroid cancer with lateral neck metastases — selective neck dissection (levels II–V).
• Colorectal cancer — en bloc lymphadenectomy is integral to standard colonic resection (minimum 12 nodes required for adequate staging per AJCC guidelines).

Selecting the right biopsy modality depends on the clinical question, node accessibility, and downstream diagnostic requirements:

Fine Needle Aspiration Cytology (FNAC):

A 22–25-gauge needle is inserted into the node under palpation or ultrasound guidance to aspirate cells for cytological smear. FNAC is rapid, minimally invasive, and can be performed in the outpatient setting under local anaesthesia. It is excellent for confirming metastatic carcinoma (sensitivity ~90%), recurrence of known malignancy, and infectious lymphadenitis. However, FNA cannot diagnose lymphoma subtype because cytology does not preserve lymph node architecture — the critical feature for WHO lymphoma classification. Flow cytometry can be added to FNA samples to support haematological diagnosis, but excisional biopsy is recommended whenever lymphoma is the primary differential.

Core Needle Biopsy (CNB):

A 14–18-gauge cutting-core needle obtains a tissue cylinder (histological core) rather than loose cells. CNB preserves tissue architecture sufficient for immunohistochemistry, gene rearrangement studies (PCR, FISH), and PD-L1 testing. Sensitivity for lymphoma diagnosis approaches 80–90% with adequate sampling (minimum 2–3 cores). CNB is preferred when the target node is deep (e.g., mediastinal, retroperitoneal — under CT or EUS guidance) or when excisional biopsy carries significant surgical risk. CNB should not substitute for excisional biopsy in suspected classic Hodgkin lymphoma or follicular lymphoma, where architectural features are diagnostically essential.

Excisional Lymph Node Biopsy:

Complete removal of an intact lymph node is the gold standard for lymphoma diagnosis. The largest and most representative accessible node should be selected — preferably under ultrasound guidance to confirm the most metabolically active node (or guided by PET-CT in FDG-avid disease). The node should be sent fresh (not in formalin) to the haematopathology laboratory to enable cell suspension for flow cytometry, cytogenetics, and molecular studies alongside formalin-fixed paraffin-embedded sections. Excisional biopsy under general anaesthesia is required for mediastinal nodes (video-assisted thoracoscopy, VATS) or retroperitoneal nodes (laparoscopic biopsy).

Sentinel Lymph Node Biopsy (SLNB) — Technical Approach

The sentinel lymph node (SLN) concept, introduced by Morton et al. (1992) for melanoma and Giuliano et al. for breast cancer, holds that the first draining lymph node from a primary tumour accurately reflects the histological status of the regional basin. Techniques for SLN identification:

• Radioisotope mapping: Technetium-99m-labelled colloid (nanocolloid in Europe; filtered sulphur colloid in the USA) is injected peritumorally 2–24 hours before surgery. A gamma probe (handheld scintillation detector) identifies the sentinel node intraoperatively. The node is considered sentinel when >10 counts/second ex vivo and >10× background in situ.
• Blue dye: Patent V blue or isosulfan blue injected peritumorally 5 minutes before incision. Visual identification of blue-stained lymphatics and nodes. When combined with radioisotope, identification rate exceeds 97–99%. Risk of anaphylaxis (~0.5–1% with blue dyes).
• Indocyanine green (ICG) near-infrared fluorescence: Increasingly used as an alternative or adjunct; real-time lymphatic mapping under near-infrared camera without radiation exposure. Sensitivity comparable to radioisotope mapping.
• SNOLL technique: For non-palpable breast lesions, radioisotope is injected around the occult lesion under ultrasound/mammographic guidance; the same injection localises both the primary tumour (for wire-free excision) and the sentinel node simultaneously.

ACOSOG Z0011 Trial — Landmark Breast Cancer Data

The Z0011 trial (n=891, T1–T2 clinically N0 breast cancer) randomised patients with 1–2 positive sentinel nodes to SLNB alone vs completion ALND. With median follow-up of 9.25 years, there was no significant difference in local-regional recurrence (1.8% SLNB vs 3.4% ALND, p=0.11), disease-free survival (78.2% vs 75.3%, p=0.32), or overall survival (86.3% vs 83.6%, p=0.24). ALND was therefore abandoned in eligible patients meeting Z0011 criteria: breast-conserving surgery, clinically node-negative, 1–2 positive SLNs, planned whole-breast radiotherapy. This paradigm shift eliminated unnecessary ALND in the majority of sentinel node-positive breast cancer patients.

MSLT-1 Trial — Melanoma SLNB Data

The Multicentre Selective Lymphadenectomy Trial-1 (n=2,001) randomised melanoma patients to SLNB ± immediate completion lymphadenectomy if SN-positive, vs observation with delayed node dissection only for clinically detectable metastases. SLNB improved staging accuracy and disease-free survival in intermediate-thickness melanomas (1.2–3.5 mm). MSLT-2 subsequently demonstrated that immediate completion dissection after a positive SN did not improve melanoma-specific survival compared to nodal observation with ultrasound, further supporting de-escalation of lymphadenectomy in sentinel node-positive melanoma without macroscopic nodal disease.

Therapeutic Lymph Node Dissection

• Axillary lymph node dissection (ALND) — Levels I, II (± III): En bloc removal of axillary fat containing lymph nodes medial to pectoralis minor (level I), posterior to pectoralis minor (level II), and medial to pectoralis minor (level III — only if level II nodes positive). Requires drain placement. Risk of injury to thoracodorsal nerve (latissimus dorsi weakness), long thoracic nerve (serratus anterior palsy — 'winged scapula'), intercostobrachial nerve (axillary numbness).
• Groin dissection (inguinofemoral lymphadenectomy): Superficial ± deep groin dissection for melanoma, vulvar, penile, and squamous cell carcinoma of the lower extremity. High wound complication rate (wound dehiscence, seroma, lymphocele — 30–50%); lymphedema in 30–40% of limbs.
• Retroperitoneal lymph node dissection (RPLND): For testicular cancer; primary RPLND for clinical stage I/II NSGCT or post-chemotherapy RPLND for residual masses. Template dissection preserves ejaculatory nerves (nerve-sparing RPLND). Laparoscopic and robotic approaches reduce morbidity.
• Cervical and neck dissection: Selective (levels IIa–V), modified radical, or radical neck dissection for thyroid, head and neck, and melanoma lymphadenectomy.

The benefits of lymph node surgery depend on the procedure type and clinical context:

• Accurate staging: Pathological nodal status is the most important prognostic factor in most solid tumours. Accurate N-staging determines adjuvant therapy decisions, surveillance intensity, and trial eligibility. SLNB provides this information with <5% false-negative rate in experienced centres.
• Therapeutic benefit of early sentinel node information: In melanoma, SLNB identifies micrometastatic disease, enabling adjuvant targeted therapy (BRAF inhibitors in BRAF-mutant disease) or immunotherapy (anti-PD1: pembrolizumab, nivolumab in stage III), shown to improve recurrence-free survival by 40–50% in adjuvant trials (KEYNOTE-716, CheckMate 238).
• Locoregional disease control: Complete lymphadenectomy for macroscopic nodal disease achieves locoregional control, preventing painful, ulcerating, or obstructing nodal masses. In some scenarios (e.g., select stage III melanoma, penile cancer), it may improve cancer-specific survival.
• Definitive diagnosis enabling curative treatment: Excisional biopsy for lymphoma provides the accurate subtype diagnosis on which curative chemotherapy selection depends (e.g., ABVD for classical Hodgkin lymphoma vs R-CHOP for DLBCL).
• Avoidance of over-treatment (SLNB): By accurately identifying node-negative patients (80–85% of clinically N0 cases), SLNB spares the majority from ALND and its associated morbidity, particularly lymphedema, shoulder dysfunction, and paraesthesia.

Complications depend significantly on the extent of lymph node surgery performed:

Diagnostic biopsies (FNA, core, excisional):

• Haematoma and seroma formation (5–10% for excisional biopsy)
• Wound infection (1–3%)
• Nerve injury (marginal mandibular branch of facial nerve during cervical node biopsy — 1–2%)
• Pneumothorax risk with mediastinal/supraclavicular biopsy (use ultrasound guidance)
• Blue dye anaphylaxis (0.5–1.5% with isosulfan blue — avoid in patients with sulphite allergy; ICG increasingly preferred)

Sentinel Lymph Node Biopsy:

• Seroma at injection site or SN basin (10–15%)
• Lymphedema of the arm: <5% after SLNB alone (vs 15–25% after ALND)
• Paraesthesia in the SN basin distribution
• Failure to identify sentinel node (false-negative rate 5–10% — higher in obese patients or prior surgery)
• False-negative rate: 5–10% — intraoperative frozen section has limited utility for micrometastases; final paraffin sections with immunohistochemistry recommended

Axillary Lymph Node Dissection (ALND):

• Lymphedema: The most significant long-term complication. Incidence is 15–25% for arm lymphedema after ALND for breast cancer (vs <5% for SLNB). Risk is increased by obesity, post-operative radiotherapy, and infection. Lifelong compression garment use and physiotherapy may be required.
• Shoulder stiffness and reduced range of motion (30–40% at 6 months, majority resolve)
• Axillary web syndrome ('cording' — 20–30%, responds to physiotherapy)
• Thoracodorsal nerve injury — latissimus dorsi weakness
• Long thoracic nerve injury — serratus anterior palsy ('winged scapula')
• Intercostobrachial nerve sacrifice — medial upper arm numbness (universal after formal ALND)

Groin/Inguinal Dissection:

• Wound complications (dehiscence, infection, lymphocele): 30–50%
• Lower limb lymphedema: 30–40% of limbs after formal groin dissection
• Deep vein thrombosis risk (LMWH prophylaxis mandatory perioperatively)

Lymphedema Prevention: All patients undergoing lymph node surgery should receive preoperative physiotherapy education, postoperative lymphedema surveillance, and referral to a certified lymphedema therapist if swelling develops.

Follow-up after lymph node excision is guided by the underlying diagnosis and extent of surgery:

Immediate post-operative care:

• Wound inspection at 7–10 days; drain removal when output <30 mL/day.
• Seroma aspiration as required (common after ALND — may need repeat aspirations weekly for 4–6 weeks).
• Early shoulder mobilisation exercises (start within 24–48 hours to prevent stiffness) — supervised physiotherapy referral for ALND patients.
• Infection vigilance — any cellulitis in the draining limb should prompt immediate antibiotic treatment to prevent or worsen lymphedema.

Lymphedema surveillance:

• Baseline circumferential arm/leg measurements before surgery.
• Post-operative measurements at each follow-up visit; perometry (optoelectronic circumference measurement) or bioimpedance spectroscopy increasingly used for early detection.
• Referral to certified lymphedema therapist (CLT) at first sign of swelling.
• Patient education: avoid blood pressure cuffs, injections, cuts, and sunburn in the at-risk limb; prompt treatment of any skin infections.

Oncological follow-up:

• Post-SLNB: oncological follow-up per primary tumour protocol. Axillary ultrasound surveillance for sentinel node-positive patients managed with SLNB alone (Z0011 protocol).
• Post-ALND/groin dissection: clinical examination of the operated basin at each oncology visit; CT or PET-CT for suspected recurrence.
• Post-excisional biopsy: haematology/oncology follow-up within 2 weeks for lymphoma treatment planning after results available.

The cost of lymph node procedures varies significantly by modality and setting:

• FNA cytology: USD 100–400 in the USA; USD 10–50 in South/Southeast Asia. Simple, widely available in most healthcare settings worldwide.
• Core needle biopsy with image guidance (ultrasound/CT): USD 500–2,000 in high-income countries; USD 50–200 in medical tourism destinations (India, Thailand, Malaysia).
• Excisional lymph node biopsy (outpatient surgical): USD 3,000–8,000 in the USA (facility + anaesthesia + pathology); USD 300–1,500 in Southeast Asia or India.
• Sentinel lymph node biopsy: USD 5,000–15,000 in the USA (includes radioisotope mapping, surgery, intraoperative gamma probe, pathology). The radioisotope mapping alone (lymphoscintigraphy) costs USD 500–1,500.
• Axillary lymph node dissection: USD 10,000–25,000 as part of breast cancer surgery in the USA; USD 2,000–5,000 in India, Thailand, or Mexico as a stand-alone procedure.
• Retroperitoneal lymph node dissection (RPLND): USD 20,000–50,000 in the USA (laparoscopic/robotic). Specialist centres in India and South Korea offer this for USD 5,000–12,000.

Insurance coverage for lymph node surgery is generally comprehensive when indicated for cancer staging or diagnosis. Lymphedema treatment (compression garments, physiotherapy) may require separate coverage. In the UK, all oncological lymph node procedures are covered by the NHS; radioisotope mapping is universally available at SLNB-accredited surgical centres.

Several emerging techniques and alternative approaches are changing lymph node management:

• Liquid biopsy (circulating tumour DNA / ctDNA): Emerging as a complement or potential future alternative to nodal staging in some cancers. In melanoma, ctDNA positivity correlates with stage III/IV disease and predicts relapse. Not yet a validated replacement for SLNB in routine practice.
• PET-CT guided assessment: In FDG-avid lymphomas and some solid tumours, PET-CT can guide biopsy to the most metabolically active node and may reduce the need for exploratory surgery to access deep nodes. PET-guided biopsy does not replace histopathology.
• Magnetic sentinel node detection (Magtrace): Iron oxide nanoparticles injected around the tumour migrate to sentinel nodes, which are then detected with a handheld magnetic probe (Sentimag). No radioactivity required — enables SN localisation without nuclear medicine facilities. Validated in the ENRICH and SentiMAG trials for breast cancer with detection rates equivalent to radioisotope.
• Targeted axillary dissection (TAD) after neoadjuvant chemotherapy: Marking the biopsy-proven positive node with a clip before chemotherapy, then performing SLNB + targeted removal of the clipped node at surgery. If all biopsied nodes convert to ypN0, ALND may be omitted. TAD reduces false-negative rates to <2% compared to 10–14% for standard SLNB post-NAC.
• Watchful waiting for sentinel node-positive melanoma (MSLT-2, DeCOG-SLT): Following positive SLNB, immediate completion lymphadenectomy has been replaced by active ultrasound surveillance in most guidelines, reserving dissection for macroscopic nodal progression — without compromise of melanoma-specific survival.
• Radiological evaluation: For lymph node assessment without biopsy: MRI with USPIO contrast agents, diffusion-weighted MRI, and elastography can improve specificity for malignant involvement. CT-guided core biopsy for deep nodal disease (mediastinal, retroperitoneal) avoids general anaesthesia.